Cipher Pharmaceuticals (TSE:CPH) Given New C$19.00 Price Target at Stifel Nicolaus

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) had its target price upped by Stifel Nicolaus from C$17.00 to C$19.00 in a research report issued to clients and investors on Thursday, BayStreet.CA reports. Stifel Nicolaus’ price target would indicate a potential upside of 15.01% from the company’s current price.

A number of other brokerages have also recently weighed in on CPH. Leede Financial cut Cipher Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, September 13th. Stifel Canada upgraded shares of Cipher Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, August 12th.

Cipher Pharmaceuticals Stock Up 2.3 %

CPH stock opened at C$16.52 on Thursday. The firm has a market cap of C$422.75 million, a PE ratio of 13.32 and a beta of 1.20. Cipher Pharmaceuticals has a 12 month low of C$4.30 and a 12 month high of C$19.69. The company has a debt-to-equity ratio of 0.33, a current ratio of 11.18 and a quick ratio of 2.67. The firm has a 50 day simple moving average of C$16.45 and a 200 day simple moving average of C$11.77.

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) last announced its quarterly earnings data on Thursday, August 8th. The company reported C$0.16 EPS for the quarter, beating analysts’ consensus estimates of C$0.15 by C$0.01. The company had revenue of C$7.26 million during the quarter, compared to the consensus estimate of C$7.52 million. Cipher Pharmaceuticals had a return on equity of 28.43% and a net margin of 102.01%. Equities research analysts forecast that Cipher Pharmaceuticals will post 1.6472868 earnings per share for the current fiscal year.

Cipher Pharmaceuticals Company Profile

Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.